~~<i id='02E2313A54'><strike id='02E2313A54'><tt id='02E2313A54'><pre id='02E2313A54'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：entertainment 2025-08-11 07:58:43 - browse：3

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： The tragedy of Johnson & Johnson’s Covid vaccine

entertainment

leisure time

knowledge

Wikipedia

explore

DistrictcourtswillmakethefirstroundofdecisionssoononchallengestoMedicare'sdrugpricenegotiationprogra

WSS

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

GSK to buy asthma

Research misconduct: Proposed new rules face resistance

Independent physicians launch a new lobbying group

Biotech reporter’s notebook: A sunnier mood at JPM 2024

The SUPPORT Act is critical to fighting the opioid crisis

explore

entertainment

entertainment

Jerome Adams on the need for new antivirals for Covid

HHS names first

Tori Bowie and the unacceptable rates of Black maternal death

Independent physicians launch a new lobbying group

In Memoriam: Notable people who died in 2023

Health and fitness trackers are measuring the wrong things

Supreme Court strikes down use of affirmative action

Think you might have Covid

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

leisure time

New England Journal of Medicine addresses racist history, slavery

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Fauci’s Covid grilling leads GOP to weigh foreign research rules

HHS names first

How digital therapeutics firms are pivoting after Pear's bankruptcy

Francis Collins on trust in science and how Covid communications failed

leisure time

knowledge

Wikipedia

explore